1. Introduction {#s0005}
===============

Neurotransmitter signaling is normally associated with the nervous system but compiling evidence suggests that many neurotransmitters exert modifying influence on cells of the immune system ([@bb0180]; [@bb0135]; [@bb0030]; [@bb0185]; [@bb0105]). The amino acid γ-aminobutyric acid (GABA) is best known as the main inhibitory neurotransmitter in the brain, but it is also present in the pancreatic islets and in blood ([@bb0020]; [@bb0225]; [@bb0095]; [@bb0190]). In the brain, GABA is made in neurons from the amino acid glutamate by the enzyme glutamic acid decarboxylase (GAD) that is present in two isoforms, GAD65 and 67 ([@bb0060]). GAD is also found in the insulin-secreting β cells in the pancreatic islets, where GAD65 is one of the main autoantigen in T1D in humans ([@bb0145], [@bb0060], [@bb0020]). Interestingly, some immune cells may also produce and release GABA ([@bb0110]; [@bb0045]). Where GABA in blood comes from is still being explored, but the recently discovered drainage system of the brain, the glymphatic system ([@bb0240]), identifies the brain, in addition to peripheral organs, as a potential source for GABA in blood. In the pancreatic islets, GABA is an auto- and paracrine signaling molecule activating GABA receptors on the endocrine cells and, perhaps, also on immune cells that may enter the islets ([@bb0050]; [@bb0145]; [@bb0065]; [@bb0035]). Similarly, in blood, immune cells may be regulated by GABA ([@bb0035]; [@bb0055]; [@bb0270]; [@bb0265]). In T1D, the β cell mass declines and, thereby, also the local source for GABA in the pancreatic islets ([@bb0100], [@bb0275]).

GABA activates two types of receptors in the plasma membrane of cells; the GABA~A~ receptors, that are Cl^−^ ion channels opened by GABA, and the G-protein-coupled GABA~B~ receptor ([@bb0195]; [@bb0210]; [@bb0215]). The GABA~A~ receptors are pentameric, homo- or heteromeric, receptors formed from 19 known subunit isoforms (α1--6, β1--3, γ1--3, δ, ε θ, π, ρ1--3) ([@bb0215]). In contrast, the GABA~B~ receptor is normally formed as a dimer of the two isoforms identified to date ([@bb0195]; [@bb0115]). GABA receptors are expressed in immune cells, but their ability to influence the functional phenotype, i.e. proliferation, migration or cytokine secretion, of the cells is still relatively unexplored ([@bb0030]; [@bb0135]). Here, we studied effects of GABA on human PBMCs and T cells from ND individuals and T1D patients. The results revealed that GABA in a concentration-dependent manner regulates release of a variety of cytokines from PBMCs and CD4^+^ T cells. In PBMCs from T1D patients, GABA significantly altered secretion of both pro- and anti-inflammatory types of cytokines.

2. Materials and Methods {#s0010}
========================

2.1. Study Individuals and Ethical Permits {#s0015}
------------------------------------------

The study was approved by Regional Ethical Review Board in Uppsala, and the reported investigations were carried out in accordance with the principles of the Declaration of Helsinki as revised in 2000. The study includes 30 healthy controls and 64 T1D patients. All participants signed a written consent form before entering the study. The participants were recruited at Uppsala University Hospital. Demographic characteristics of the participants are summarized in Table S1. All the participants were screened for islet autoantibodies (GAD and islet antigen-2, IA2), which were not present in any of the healthy controls. None of the healthy controls had a first degree relative diagnosed with T1D. None of the participants was ill from, or had recently recovered from, an infectious disease. All blood samples were collected in the morning after an overnight fasting under standardized conditions. Routine lab parameters were analyzed at the Central Clinical Chemistry Laboratory, Uppsala University Hospital. The venous blood samples were collected in EDTA tubes and processed for further experimentation.

2.2. Plasma, PBMCs and T Cell Isolation {#s0020}
---------------------------------------

Plasma, PBMCs and T cells were isolated from freshly derived blood samples and CD4^+^ T cells from buffy coats as previously described ([@bb0035]; [@bb0040]). The plasma was isolated by centrifugation at 3600 rpm for 10 min at 4 °C directly after collection of blood, and immediately frozen at −80 °C.

The blood samples or buffy coats were diluted in 1:1 ratio in MACS buffer (Miltenyi Biotec, Madrid, Spain), and layered on Ficoll-paque plus (Sigma-Aldrich, Hamburg, Germany). Briefly, the samples were then subjected to density gradient centrifugation at 400*g* for 30 min at room temperature. The PBMCs were carefully withdrawn and washed twice in MACS buffer. A portion of PBMCs was saved in RNAlater (Sigma-Aldrich) at −80 °C for mRNA extraction for qPCR, and other portions were used for either proliferation experiments or isolation of T cells using human CD3 MicroBeads and human CD4^+^ T Cell Isolation Kits (Miltenyi Biotec). The CD3^+^ T cells were used for RNA sequencing, and the CD4^+^ T cells were used for proliferation and electrophysiological patch-clamp experiments.

2.3. Total RNA Isolation, Real-Time Quantitative Reverse Transcription PCR and Western Blot Analysis {#s0025}
----------------------------------------------------------------------------------------------------

Total RNAs were extracted with RNA/DNA/Protein Purification Plus Kit (Norgen Biotek, Ontario, Canada). The real-time qPCR method has been described previously ([@bb0260], [@bb0035], [@bb0155], [@bb0170], [@bb0040]). The extracted total RNA was quantified using Nanodrop (Nanodrop Technologies, Thermo Scientific, Inc., Wilmington, DE, USA). Then, 1.5 μg RNA was treated with 0.6 U DNase I (Roche, Basel, Switzerland) for 30 min at 37 °C to degrade genomic DNA in the sample, and then with 8 mM EDTA for 10 min at 75 °C for inactivation of DNase I enzyme. The cDNA was then synthesized using Superscript IV reverse transcriptase (Invitrogen, Stockholm, Sweden) in a 20 μl reaction mixture using standard protocol provided by manufacturer. To confirm efficient degradation of genomic DNA by DNase I treatment, we performed reverse transcriptase negative reaction which did not yield any amplification in real-time PCR, confirming the absence of genomic DNA contamination. The gene-specific primer pairs are listed in Table S2. The real-time qPCR amplification was performed on an ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems) in a standard 10 μl reaction with an initial denaturation step of 5 min at 95 °C, followed by 45 cycles of 95 °C for 15 s, 60 °C for 30 s and 72 °C for 1 min, followed by melting curve analysis.

Protein extraction from PBMC samples was performed using RNA/DNA/Protein Purification Plus Kit (Norgen Biotek, Ontario, Canada). Protein amounts were quantified using the RC DCTM protein assay kit (Bio-Rad, USA) in Multiskan MS plate reader (Labsystems, Vantaa, Finland), and the concentration was calculated by plotting standard curve. Protein samples (60 μg) were subjected to SDS-PAGE using 10% polyacrylamide gels and transferred to PVDF membranes (Thermofisher Scientific, Stockholm, Sweden). The membranes were blocked with 5% non-fat milk powder in Tris buffered saline containing 0.1% Tween (TBS-T) for 1 h and incubated overnight at 4 °C with primary antibodies against NKCC1 (1:2000; Cell Signaling Technology, Cat No. 8351, USA), GABA~A~R ρ2 (1:500; Abcam, Cat No. ab83223, Cambridge, UK) and GAPDH (1:3000; Merck Millipore, Cat No. ABS16, USA). After 3 washings with TBS-T, the membranes were further incubated with horseradish peroxidase-conjugated secondary antibody (1:3000; Cell Signaling Technology, Cat No. 7074) for 2 h and then the immunoreactive protein bands were visualized by enhanced chemiluminescence (ECL) detection kit (Thermofisher Scientific, Stockholm, Sweden).

2.4. Determination of GABA Concentration {#s0030}
----------------------------------------

Plasma samples were thawed, and the level of GABA was measured using an ELISA kit (LDN Labor Diagnostika Nord, Nordhorn, Germany) as per manufacturer\'s guidelines ([@bb0110]; [@bb0005]; [@bb0090]; [@bb0175]). Briefly, the plasma samples and standards provided in the kit were extracted on extraction plate, derivatized using equalizing reagent and subjected to standard competitive ELISA in GABA coated microtiter strips. The absorbance of the solution in the wells was read at 450 nm within 10 min using a Multiskan MS plate reader (Labsystems, Vantaa, Finland). We used 620 nm as a reference wavelength. The outcome of the assay, optical density values, were used to plot the standard curve for each run, which was then used to interpolate the GABA concentration of the samples. The readout obtained by the GABA standards in the kit was compared to and agreed with the standards in the quality control (QC) report from the company (Fig. S1).

2.5. Electrophysiology {#s0035}
----------------------

GABA-activated currents were recorded by the patch-clamp technique as previously described ([@bb0055]; [@bb0130]). The extracellular recording solution contained (in mM): 145 NaCl, 3 KCl, 1 CsCl, 1 CaCl~2~, 1 MgCl~2~, 10 glucose and 10 TES; the pH was adjusted to 7.4 with NaOH. To record in the whole-cell configuration, the pipette solution contained (in mM): 136 CsCl, 20 KCl, 1 MgCl~2~, 3 MgATP and 10 TES; pH was adjusted to 7.3 with CsOH. The pipette solution for the cell-attached configuration contained (in mM): 69 NaCl, 5 KCl, 75 CsCl, 1 CaCl~2~, 1 MgCl~2~ and 10 TES; pH was adjusted to 7.4 with NaOH. Saclofen (a GABA~B~ receptor antagonist, 200 μM) and GABA (100 nM) were used in the experiments. The pipette potential (V~p~) was −80 mV (hyperpolarizing) in the whole-cell configuration and −60 mV (depolarizing) in the cell-attached configuration.

2.6. Proliferation Assay {#s0040}
------------------------

The proliferation of freshly isolated human PBMCs or CD4^+^ T cells was evaluated with MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay ([@bb0255]). Cells were suspended in complete medium (RPMI 1640 supplemented with 2 mM glutamine, 25 mM HEPES, 10% heat inactivated fetal bovine serum, 100 U/ml penicillin, 10 mg/ml streptomycin, 5 mM β-mercaptoethanol) in a concentration 1 million cells per milliliter. The assay was performed in 96-well plates in duplicates or triplicates, where each well was pre-coated with 3 μg/ml anti-CD3 antibody for 3--5 h at 37 °C. Each well was loaded with 100,000 cells. Drugs were added to the wells at the relevant concentrations. The plate was incubated for 68 h at 37 °C (95% O~2~, 5% CO~2~) and then, a media-soluble tetrazolium dye MTT was added to a final concentration of 1 mM after which the plate was incubated for additional 4 h. The plate was then centrifuged at 2000 RPM for 10 min to pellet the insoluble purple formazan crystals. The supernatant culture media was collected, stored at −80 °C and used for analysis of cytokines using the multiplex proximity extension assay (PEA). The formazan crystal pellet was dissolved in DMSO and the plate was read within 10 min using a Multiskan MS plate reader (Labsystems) at 550 nm. The optical density value was used as the proliferation index value. Drugs were purchased from Sigma-Aldrich or Tocris (Bristol, UK).

2.7. Multiplex PEA for Cytokine Measurements {#s0045}
--------------------------------------------

Plasma samples, and culture media samples that were collected from plate wells at the end of the proliferation assay, were analyzed by multiplex PEA with an Olink Inflammation I^96X96^ panel, targeting 92 proteins related to inflammation (Olink Proteomics, Uppsala, Sweden) as previously described ([@bb0085]; [@bb0015]; [@bb0165]; [@bb0160]). Briefly, 1 μl of sample (plasma samples or cell culture media samples) or negative control was mixed with 3 μl probe solution containing a set of 92 paires DNA-oligonucleotide-conjugated antibodies. Upon recognition of a target protein by a pair of probes, the DNA oligonucletodies on the antibodies are brought in proximity and hybridize to each other, follwed by enzymatic DNA polymerization to form a new DNA molecule. The newly formed DNA molecule is then amplified and quantified using a microfluidic real-time qPCR, BioMarkTM HD (Fluidigm, South San Francisco, CA, USA). The generated quantification cycle (Cq) values are normalized against spiked-in controls to convert Cq values to Normalized Protein eXpression (NPX) value on log2 scale. NPX is an arbitrary unit, which is positively correlated to protein concentration. These NPX data were then converted to linear data, using the formula 2^NPX^, prior to further statistical analysis. Limit of detetion (LOD) for each protein was defined as three standard deviations above the background. Proteins with levels below LOD were excluded from further data analysis.

2.8. Total RNA Isolation and T Cell RNA Sequencing {#s0050}
--------------------------------------------------

Total RNA was extracted from T cells using Direct-zol™ RNA MicroPrep (Zymo Research, Irvine, CA, USA) according to manufacturer\'s recommendation. cDNA libraries were prepared according to Smart-seq2 protocol ([@bb0230]). For Illumina sequencing libraries, 2 ng of cDNA was fragmented, amplified ([@bb0235]), pooled and sequenced on Illumina HiSeq 2500. Single-end 43 bp reads were generated and mapped to human reference genome GRCh38 by employing STAR (version 2.4.1) with parameter outSAMstrandField intronMotif ([@bb0075]). Reads per kilobase transcript per million mapped reads (RPKM) from RefSeq gene annotations were calculated using RPKM for genes ([@bb0245]). The uniquely mapped reads were considered for the downstream analyses.

2.9. Statistical Analysis {#s0055}
-------------------------

Statistical analysis and data mining were performed using Statistica 12 (StatSoft Scandinavia, Uppsala, Sweden), GraphPad Prism 7 (La Jolla, CA, USA) and edgeR bioconductor package. The statistical tests were performed after omitting outliers identified by the Tukey test. The differences between groups were assessed by nonparametric Kruskal--Wallis ANOVA on ranks with Dunn\'s post hoc test. The contingency of sex equality was accessed by Fisher\'s exact test. Comparison of demographic data between the two groups was based on a non-parametric Mann-Whitney test for non-normally distributed data and a two-tailed Student\'s *t*-test for normally distributed. Normality of data was assessed by D\'Agostino & Pearson omnibus normality test. The correlation between inflammatory cytokines and demographic factors was assessed using non-parametric Spearman rank correlation. The significance level was set to *p* \< 0.05.

3. Results {#s0060}
==========

Demographic data for the ND individuals (*n* = 30) and the individuals with T1D (*n* = 64) that participated in the study is presented in Table S1. As expected the individuals with T1D had higher levels of fasting glucose and HbA1c (Table S1). In addition, the individuals with T1D were, on the average, slightly older and had a higher BMI (Table S1). The creatinine levels did not differ between the two groups but the glomerular filtration rate was higher in the diabetes group (Table S1). Islet autoantibodies (GAD and IA2) were not detected in any of the healthy individuals.

3.1. Cytokines in Plasma From ND and T1D Individuals {#s0065}
----------------------------------------------------

Immune cells secrete a large number of small proteins, collectively termed cytokines, which may have a protective function or act as pro-inflammatory molecules. We investigated whether the types of cytokines in plasma differed between ND individuals and T1D patients. We used the multiplex PEA to measure the blood levels of a panel of 92 cytokines that are most commonly associated with inflammation (<http://www.olink.com/products/inflammation/>\#). The assay that uses paired cytokine-specific antibodies for the different cytokines allows comparison of the levels of the same cytokine in samples from e.g. ND individuals and T1D patients. However, the assay format does not support comparison of the absolute levels of one cytokine to another as the affinities of the antibodies for their cognate targets may vary. As illustrated in [Fig. 1](#f0005){ref-type="fig"}a, 73 out of 92 analyzed cytokines were detected in plasma from the donors, of which 26 cytokines were significantly up-regulated and only one cytokine, FGF-21 down-regulated in plasma from T1D patients as compared to ND individuals ([Fig. 1](#f0005){ref-type="fig"}b).Fig. 1Cytokines in plasma from ND and T1D individuals and identification of those that correlate with plasma GABA concentration. (a) Screening of 92 inflammatory cytokines in plasma samples from ND (*n* = 30) and T1D individuals (*n* = 64) by Olink Multiplex PEA inflammation panel I detects expression of 73 cytokines. Data is presented by 2^NPX^ (Normalized Protein Expression) values as floating bars (minimum to maximum) arranged in descending order of mean expression level of cytokines. (b) Inflammatory cytokines with significant change in the expression levels in the plasma of T1D as compared to ND individuals. Data is shown as box and whiskers overlapped with scatter dot plot. (c) Quantification of GABA levels in plasma samples from ND and T1D individuals. (d) Correlation between GABA levels and cytokine levels in plasma samples from ND individuals and T1D individuals. Only cytokines with significant correlation are shown. R values are given in Table S3. \**p* \< 0.05, \*\**p* \< 0. 01, \*\*\**p* \< 0.001.Fig. 1

We then examined if the neurotransmitter GABA varied in concentration in plasma between the ND and T1D individuals ([Fig. 1](#f0005){ref-type="fig"}c). The GABA concentration range was similar for the two groups but there was a trend for increased plasma GABA concentration in T1D patients resulting in a significantly higher average concentration in the T1D group (ND: 501 ± 32 nM; T1D: 649 ± 42 nM; *p* \< 0.05). No correlation was observed for GABA concentrations with age or disease duration. In contrast, when the concentration of GABA was correlated with cytokines detected in plasma, levels of 10 cytokines were significantly correlated (p \< 0.05) with the plasma GABA concentration ([Fig. 1](#f0005){ref-type="fig"}d; Table S3).

3.2. GABA Inhibits Proliferation of PBMCs From T1D Patients and Responder CD4^+^ T Cells {#s0070}
----------------------------------------------------------------------------------------

To further examine the effects of GABA on the immune cells, we stimulated PBMCs and CD4^+^ T cells with anti-CD3 antibody to induce proliferation of CD3^+^ positive T cells. We then examined effects on proliferation of GABA and the GABA~A~ antagonist, picrotoxin. In PBMCs from ND individuals, GABA did not inhibit proliferation of the cells ([Fig. 2](#f0010){ref-type="fig"}a). In contrast, cell proliferation of PBMCs from T1D patients was inhibited in the presence of 100 nM GABA by approximately 20%, while GABA at concentration of 1 μM did not have any inhibitory effect on the cell proliferation. The inhibition was reversed by picrotoxin ([Fig. 2](#f0010){ref-type="fig"}b). We have previously demonstrated that GABA may inhibit T cells proliferation ([@bb0055]) and, thus, examined whether CD4^+^ T cells from ND individuals varied in their sensitivity to GABA. The results revealed that CD4^+^ T cells from the ND individuals could be grouped into responders (*n* = 15) and non-responders (*n* = 7) depending on whether or not GABA affected the proliferation of the cells ([Fig. 2](#f0010){ref-type="fig"}c). We examined further if GABA, in a dose-dependent manner, could regulate proliferation of the responder CD4^+^ T cells ([Fig. 2](#f0010){ref-type="fig"}d). Application of different GABA concentrations demonstrated increased inhibition of proliferation from 1 to 500 nM GABA with a maximum inhibition of approximately 40% by 500 nM GABA, whereas no inhibition of proliferation of the cells was recorded in 1 μM GABA ([Fig. 2](#f0010){ref-type="fig"}d). This is in line with the fact that saturating GABA concentrations cause desensitization and thus, non-functionality of GABA~A~ receptors. The open channel blocker picrotoxin partially reversed the 500 nM GABA-induced inhibition ([Fig. 2](#f0010){ref-type="fig"}e) and the GABA~A~ agonists muscimol (100 nM) and TACA (100 nM) inhibited the proliferation similar to GABA ([Fig. 2](#f0010){ref-type="fig"}f), whereas the GABA~B~ antagonist CGP52432 (50 μM) and the GABA~B~ agonist baclofen (100 nM) were ineffective ([Fig. 2](#f0010){ref-type="fig"}e, f). Together the results highlight that immune cells and in particular CD4^+^ T cells can be divided into subgroups depending on whether or not their proliferation is regulated by GABA. The greater inhibition observed for the PBMCs from the T1D patients as compared to ND individuals is consistent with the presence of expanded T cells clones that respond to GABA in T1D ([@bb0280]).Fig. 2GABA activation of GABA~A~ receptors inhibits proliferation of PBMCs and responder CD4^+^ T cells from T1D and ND individuals. Effects of GABA and GABA~A~ receptors antagonist, picrotoxin, on proliferation of PBMCs from (a) ND individuals and (b) T1D individuals. (c) Effect of GABA on proliferation of CD4^+^ T cells from ND individuals identifying GABA non-responder (orange) and GABA responder (magenta) populations of CD4^+^ T cells. (d) GABA dose-dependent inhibition of proliferation of responder CD4^+^ T cells. (e) Effects of GABA~A~ (picrotoxin, muscimol, TACA) and GABA~B~ (CGP 52432, baclofen) receptor antagonists and (f) agonists on proliferation of responder CD4^+^ T cells. (g) Expression of GABA~A~Rs and GABA~B~R subunits and (h) chloride transporters in PBMCs from ND individuals and T1D patients. Data are presented as normalized mRNA expression (2^-ΔCt^). (i) GABA-activated single-channel current measurements from CD4^+^ T cells from ND individuals. In the whole-cell and cell-attached configurations single-channel currents were activated by 500 and 100 nM GABA application, respectively, and inhibited by picrotoxin (PTX, 100 μM). \# marks single-channel events with typical current amplitudes at the given V~p~. (j) A volcano plot for T cell mRNA sequencing expression data as log~2~ (fold change in T1D T cells compared to ND T cells) against --log~10~ (false discovery rate). The *p* values are shown in Table S5. \*p \< 0.05, \*\*p \< 0. 01, \*\*\*p \< 0.001.Fig. 2

GABA can potentially activate GABA~A~ and GABA~B~ receptors in the immune cells ([@bb0270]; [@bb0055]; [@bb0035]). We, therefore, measured the expression level of the GABA~A~ and GABA~B~ receptor subunits in PBMCs. The most prominent GABA~A~ receptor subunit was the ρ2 that was similarly expressed and present in most samples from both ND and T1D individuals ([Fig. 2](#f0010){ref-type="fig"}g, Table S4). Protein expression of ρ2 was confirmed by western blot analysis (Fig. S2). Of the two GABA~B~ receptor subunits, only the GABA~B~R1 was commonly expressed. Our results confirmed previously reported expression of GABA receptors in PBMCs ([@bb0035]). We further found that the mRNA expression levels of auxiliary proteins of GABA~A~ receptors gephyrin and GABARAP were similar but the GABA transporters GAT3, BGT1 and the enzyme GABA-T plus the insulin receptor were significantly increased, whereas the expression level of radixin decreased in PBMCs from T1D individuals (Fig. S3, Table S4). Interestingly, expression of Cl^−^ transporters was altered in T1D ([Fig. 2](#f0010){ref-type="fig"}h). The transporter that moves Cl^−^ into the cell, NKCC1, was significantly down-regulated, whereas the transporters that move Cl^−^ out of the cells, KCC3 and KCC4, were up-regulated in PBMCs from T1D patients. Protein expression of NKCC1 was confirmed by western blot analysis (Fig. S2). Since the effects of GABA~A~ receptors are related to the Cl^−^ equilibrium potential in the cells, any changes in intracellular chloride will have consequences for GABA~A~ signaling. We further investigated if GABA in submicromolar (100 or 500 nM) concentrations activated single-channel currents in the T cells. GABA activated GABA~A~ single-channel currents in the cells (*n* = 54), which were blocked by picrotoxin. The GABA~A~ receptors conductance ranged from 9 to 45 pS ([Fig. 2](#f0010){ref-type="fig"}i).

3.3. Cholesterol Biosynthesis Gene Levels Are Regulated in T Cells From T1D Patients {#s0075}
------------------------------------------------------------------------------------

We applied RNA-seq to examine the transcriptome of isolated CD3^+^ T cells from ND individuals and T1D patients ([Fig. 2](#f0010){ref-type="fig"}j). A total of 16,684 genes were identified after passing the quality control and deposited at GEO database ([GSE111876](ncbi-geo:GSE111876){#ir0010}). To reduce the bias of genes with low counts and only expressed in a few samples, we used the dataset with 8669 genes that are expressed in \>1/3 of the samples (RPKM\>5) in both T1D patients and ND individuals. Eleven genes (edgeR *p* \< 0.05, FDR \< 0.05) were differentially expressed by more than two-fold between T1D and ND samples, of which only 1 gene (*SCARNA21*) was up-regulated and 10 genes were down-regulated in samples from T1D patients ([Fig. 2](#f0010){ref-type="fig"}j). Among the down-regulated genes, 5 genes (*SQLE, MSMO1, DHCR24, CYP51A1, HMGCS1*) are involved in the cholesterol biosynthesis pathway and 1 gene (*INSIG1*) encodes an endoplasmic reticulum protein that regulates cholesterol biosynthesis (REACTOME, <http://reactome.org>) (Table S5). Interestingly, the expression levels of *MSMO1* and *CYP51A1* were significantly correlated with the plasma GABA concentration (p \< 0.05) (Fig. S4). Furthermore, the expression of *MSMO1* was also significantly correlated with BMI, fasting glucose and HbA1c levels (p \< 0.05) (Fig. S4).

3.4. GABA Regulates Release of Pro- and Anti-inflammatory Cytokines From PBMCs {#s0080}
------------------------------------------------------------------------------

It is possible that GABA signaling regulates what cytokines are released from the immune cells. We, therefore, examined the culture media from the anti-CD3 stimulated PBMCs using the inflammatory related protein panel described above to study which of the 92 cytokines are released by the cells and whether GABA affects secretion of specific cytokines. [Fig. 3](#f0015){ref-type="fig"}a shows the levels of the different cytokines detected in the culture media harboring proliferating cells from ND individuals and T1D patients. In the absence of GABA, a difference in the secretion level was observed for six cytokines ([Fig. 3](#f0015){ref-type="fig"}a insert). Somewhat surprisingly, the results shown in [Fig. 3](#f0015){ref-type="fig"}b and c and also Table S6 and S7 demonstrate that GABA regulated the release of many pro- and anti-inflammatory cytokines. In the culture media from stimulated PBMCs, GABA (100 nM) significantly inhibited release of 16 cytokines from ND individuals (*n* = 7; [Fig. 3](#f0015){ref-type="fig"}b) and 47 cytokines from T1D patients (*n* = 13; [Fig. 3](#f0015){ref-type="fig"}c), respectively, and, additionally, increased the release of two cytokines from T1D patients ([Fig. 3](#f0015){ref-type="fig"}c). Cytokines released by stimulated PBMCs, which were affected by GABA can be grouped according to their function ([Fig. 3](#f0015){ref-type="fig"}d). The group of cytokines with the largest difference between ND and T1D PBMCs was the one associated with chemotaxis. The results are in agreement with that GABA regulates release of cytokines from PBMCs in both health and in disease.Fig. 3Identification of cytokines released into the culture media and effects of GABA treatment on the PBMCs cytokine secretion. (a) Screening of 92 cytokines in media from PBMCs from ND individuals or from T1D individuals, by Olink Multiplex PEA inflammation panel I, revealed expression of 63 cytokines. No GABA was added to the media. Data are represented by 2^NPX^ values as floating bars (minimum to maximum) arranged in descending order of mean expression level of cytokines. Insert show cytokines with significant change in the expression levels in the media of PBMCs from ND individuals as compared with T1D individuals. Data are plotted as a bar graph with mean ± SEM. (b-c) Expression of cytokines that are significantly affected by GABA 100 nM treatment of PBMCs from (b) ND individuals and from (c) T1D individuals. Data are represented by 2^NPX^ values normalized to controls as a bar graph with mean ± SEM. Mean values with SEM and p values are shown in Tables S6 and S7. (d) Classification based on the cellular functions of cytokines that were significantly altered by GABA 100 nM treatment of PBMCs from ND individuals (16 cytokines) and from T1D individuals (49 cytokines).Fig. 3

3.5. GABA Regulates Release of Pro- and Anti-inflammatory Cytokines From CD4^+^ T Cells {#s0085}
---------------------------------------------------------------------------------------

ND individuals could be divided into two groups based on whether or not their stimulated CD4^+^ cells responded to GABA in the proliferation assay (see [Fig. 2](#f0010){ref-type="fig"}c). We termed the two groups of stimulated CD4^+^ cells, responder (*n* = 15) and non-responder (n = 7) T cells. Stimulated T cells normally release more and higher levels of cytokines than resting T cells (Fig. S5). We examined if CD4^+^ T cells from responders and non-responders differentially secreted cytokines and then, if the release in the two groups were affected by GABA. [Fig. 4](#f0020){ref-type="fig"}a shows that upon stimulation, cells from both groups released a number of cytokines and to similar levels. Only levels of three cytokines were significantly different between the two groups ([Fig. 4](#f0020){ref-type="fig"}a insert). In contrast regulation of cytokine release by GABA was far more prominent in the responder as compared to the non-responder T cells. In non-responder T cells, GABA at 100 and 500 nM concentration regulated secretion of only four cytokines at each concentration ([Fig. 4](#f0020){ref-type="fig"}b, c; Table S8). This is in contrast to the responder T cells where GABA significantly inhibited release of many cytokines and, interestingly, the different concentrations of GABA inhibited release of somewhat different cytokines ([Fig. 4](#f0020){ref-type="fig"}b, c; Table S9). In the presence of 100 nM GABA, release of 27 cytokines were significantly decreased as compared to 25 cytokines in the presence of 500 nM GABA. Picrotoxin reversed the effects of GABA. Of these cytokines, secretion of 15 cytokines, including both Th1- and Th2-type cytokines e.g. TNF-α and IL-13, were inhibited by both 100 and 500 nM GABA ([Fig. 5](#f0025){ref-type="fig"}b). In the presence of 100 nM GABA, another 12 distinct cytokines, including the Th2-type IL-6 and IL-24 cytokines, were specifically inhibited. Inhibition of the Th1-type cytokines INF-γ and TNF-β plus the Th2-type cytokine IL-5 was observed only when GABA was present at 500 nM concentration. [Fig. 4](#f0020){ref-type="fig"}d shows that the proportion of cytokines associated with chemotaxis remained similar to what was determined for PBMCs from T1D patients. However, when the GABA concentration was increased from 100 to 500 nM, the proportion of cytokines associated with secretion and MAPK decreased, whereas those associated with cellular response to cytokine stimulus and regulation of immune response increased. The results demonstrate that GABA in a concentration-dependent manner regulates cytokine secretion from CD4^+^ T cells.Fig. 4Identification of cytokines released into the culture media and effects of GABA treatment on CD4^+^ T cells cytokine secretion (a) Screening of 92 cytokines in culture media from GABA non-responder and from GABA responder CD4^+^ T cells, by Olink Multiplex PEA inflammation panel I, revealed expression of 64 cytokines. No GABA was added to the media. Data are represented by 2^NPX^ values as floating bars (minimum to maximum) arranged in descending order of mean expression level of cytokines. Insert show cytokines with significant change in the expression levels in the media of GABA non-responder and GABA responder CD4^+^ T cells. Data are plotted as a bar graph with mean ± SEM. (b-c) Cytokines with significant change in the expression levels after (b) 100 nM GABA or (c) 500 nM GABA treatment of non-responder and responder CD4^+^ T cells, and then in the presence of GABA plus 100 μM picrotoxin (lower panel b, c). Mean and SEM for CXCL11, CCL19 and CCL20 are 1.55 ± 0.51, 1.72 ± 0.74, 1.43 ± 0.51, respectively. Data are represented by 2^NPX^ values normalized to controls as a bar graph with mean ± SEM. Mean values with SEM and p values are shown in Tables S8, S9. (d) Classification based on the cellular functions of cytokines that were significantly altered by GABA 100 nM (27 cytokines) and GABA 500 nM (25 cytokines) treatment of responder CD4^+^ T cells from ND individuals.Fig. 4Fig. 5GABA and T1D regulate secretion of cytokines. (a) Purple circle: responder CD4^+^ T cell cytokines regulated by GABA (100 nM, 500 nM). Light blue circle: T1D PBMC cytokines regulated by GABA (100 nM). Dark blue circle: cytokines significantly altered in plasma from T1D patients as compared to ND individuals. (b) The cytokines regulated by 100 nM or 500 nM GABA or both concentrations.Fig. 5

4. Discussion {#s0090}
=============

The results identify GABA as a potent regulator of cytokine secretion from human PBMCs and CD4^+^ T cells. GABA altered proliferation and cytokine secretion in a concentration-dependent manner and decreased the release of most of the cytokines. Importantly, immunomodulatory submicromolar GABA concentrations are normally present in plasma of both ND individuals and T1D patients.

We and others have shown that immune cells express the genes, proteins and functional GABA~A~ receptors and also the genes encoding the chloride transporters that regulate the intracellular chloride concentration in the cells ([@bb0270], [@bb0055], [@bb0045], [@bb0035], [@bb0010], [@bb0205], [@bb0135]). The most prominent GABA~A~ subunit in the PBMCs is the ρ2 subunit that can form homomeric or heteromeric receptors ([@bb0220], [@bb0285], [@bb0140], [@bb0035]). Interestingly, subtypes of GABA~A~ receptors in the brain rarely contain the ρ2 subunit ([@bb0215]) making the ρ2-containing GABA~A~ receptors in the immune cells, potentially, a rather specific target for drug-development aimed at GABA signaling in immune cells.

In T1D, the mass of the pancreatic islet β cells is greatly diminished ([@bb0025], [@bb0020]), highlighting that GABA in blood must be maintained by another mechanism than secretion from the pancreatic islets. An important source supplying GABA to blood might be the brain, by the way of the newly discovered mechanism of volume-transmission of small molecules from the brain, via the glymphatic system, to the periphery ([@bb0240]). In pancreatic islets where the β cells are intact and secrete GABA, as in ND individuals, the islet interstitial GABA concentrations can be expected to fall within the GABA immunomodulatory range. In contrast, GABA immunosuppression in pancreatic islets of T1D patients is likely to decrease as the disease progresses and the β cells disappear.

This study reveals that GABA regulates secretion of a far greater number of cytokines than was previously known. In plasma of T1D patients, levels of 26 cytokines were increased and of those, 16 were inhibited by GABA in the cell assays ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}). Moreover, of the 10 cytokines in plasma that correlated with the GABA plasma concentration, 7 cytokines were significantly increased in T1D patients and 5 of those (Flt3L, TRAIL, TNF-β, PD-L1, IL-10) were inhibited by GABA in the cell assays ([Figs. 1](#f0005){ref-type="fig"}d and [5](#f0025){ref-type="fig"}). The few studies that previously have examined effects of GABA on cytokine secretion in immune cells, have only identified a limited number of cytokines e.g. IL-1β ([@bb0045]), IL-2 ([@bb0265]), IFNγ ([@bb0270]), TNF-α ([@bb0080]) and IL-6, IL-12 ([@bb0250]). Our study revealed that about three times more cytokines were inhibited by GABA in stimulated PBMCs from T1D individuals (47 cytokines) as compared to stimulated PBMCs from ND individuals (16 cytokines). We and others have previously shown that GABA can regulate proliferation of immune cells ([@bb0265]; [@bb0055]; [@bb0135]; [@bb0070]; [@bb0200]; [@bb0270]). In this study, we used this effect of GABA to divide the stimulated CD4^+^ T cell samples from ND donors into non-responder and responder groups in terms of proliferation and then, examined how these groups differed in cytokine secretion. GABA effectively decreased proliferation and secretion of cytokines only in the responder group. Here GABA decreased secretion of 37 cytokines in a concentration-dependent manner. Of the inhibited cytokines from T1D stimulated PBMCs and the responder cells, 29 cytokines were common to both cell populations ([Fig. 5](#f0025){ref-type="fig"}a). Although the GABA-induced immunosuppression was somewhat similar for the responder and T1D cell populations, it clearly differed for a number of specific cytokines ([Fig. 5](#f0025){ref-type="fig"}a). Furthermore, GABA did not decrease proliferation of stimulated ND PBMCs nor proliferation or cytokine secretion in the non-responder T cell population. The dramatic effect GABA had on stimulated T1D PBMCs and responder T cell but not on non-responder T cells, implies that GABA is a central molecule determining cytokine secretion in primed, activated cells. It is possible that GABA has a homeostatic role in the immune system acting as a "brake" but not a "full stop".

GABA inhibited cytokines involved in chemotaxis in stimulated T1D PBMCs more than in ND PBMCs cells. When the GABA concentration was increased from 100 to 500 nM for the stimulated responder T cells, the prominence of inhibited cytokines associated with secretion and MAPK was decreased. In contrast, inhibition of cytokines that affect either the cellular response to cytokine stimulus or regulate the immune response increased in 500 nM GABA. The specific profile of cytokines regulated by GABA indicates that the 100 nM GABA response tended to modulated levels of Th2-type cytokines, whereas the 500 nM GABA inhibited both Th1- and Th2-type cytokine release ([Fig. 5](#f0025){ref-type="fig"}a, b). The results are consistent with a concentration-dependent immunomodulatory effect of GABA.

Interestingly, of the 10 genes down-regulated more than two-fold in the CD3^+^ T cells from T1D individuals, six were associated with cholesterol biosynthesis ([Fig. 2](#f0010){ref-type="fig"}j) and included *MSMO1* and *CYP51A1* that correlated negatively with the plasma GABA concentrations (Fig. S4). *MSMO1* further correlated negatively with HbA1c, fasting glucose and BMI raising the question of its potential suitability as a biomarker in T1D. Non-random distribution of proteins in the cell membranes are dependent on e.g. cholesterol and the actin cytoskeleton ([@bb0120]). The T cell receptor resides in lipid rafts that are microdomains within the plasma membrane and where cholesterol is an essential component and contributes to membrane fluidity and signal transduction ([@bb0150]; [@bb0125]). The change in cholesterol biosynthesis genes observed in the T1D T cells are likely to have an impact on signaling processes associated with signaling complexes located in the cell membrane.

The general inhibitory effect of GABA on the release of cytokines from the immune cells was enlightening. It lends further support to the immunomodulatory function of GABA ([@bb0135]; [@bb0030]; [@bb0100]). It also highlights the importance of extracellular GABA in the blood and in tissues such as the pancreatic islets and the brain. Clearly, future studies are required to identify and characterize the various subpopulations of immune cells with respect to their response to GABA and further determine how GABA, in a concentration-dependent manner, manages to differentially regulate secretion of cytokines from the cells.
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